UNSPSC 51343107: Fiacitabine

This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C9H11FIN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4058H365ZB, chemically known as 2(1h)-pyrimidinone, 4-amino-1-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-5-iodo- but generally known as fiacitabine, which bears US NIH Compound Identifier 50312. European Medicines Agency schedules Fiacitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07621MIG.

UNSPSC 51343107 Fiacitabine, a Commodity code, shows little relevant recent activity. The two state and local opportunities tagged under this code involve naloxone and safe drug deactivation systems procurement (Seminole County, Florida) and a completed pharmaceutical warehouse award for doxycycline and ciprofloxacin (Illinois Department of Public Health), neither of which align with fiacitabine's scope as a therapeutic pharmaceutical product. The mismatch between the code's nominal focus and actual solicitation content suggests either tagging inconsistency or that fiacitabine procurement among state and local bodies is minimal relative to other pharmaceutical categories tracked in the UNSPSC taxonomy.

The source does not report open solicitations for fiacitabine itself. The Illinois award to Chartwell Rx LLC through the MMCAP Infuse consortium (completed August 28, 2026, total contract value $2,999,999.11 over three years) and the Seminole County IFB for naloxone and deactivation systems (posted June 30, 2026, due July 26, 2023) represent the recent procurement activity indexed under this code, but neither represents demand for fiacitabine. State procurement professionals evaluating this code should cross-reference related pharmaceutical procurement categories or verify whether state formulary adoption or Medicaid coverage expansions are driving fiacitabine demand through alternative coding paths.